Hepatitis B Precore Protein: Pathogenic Potential and Therapeutic Promise
Yonsei Medical Journal
;
: 875-885, 2012.
Artigo
em Inglês
| WPRIM
| ID: wpr-173363
ABSTRACT
Hepatitis B virus (HBV), a small and economically packaged double-stranded DNA virus, represents an enormous global health care burden. In spite of an effective vaccine, HBV is endemic in many countries. Chronic hepatitis B (CHB) results in the development of significant clinical outcomes such as liver disease and hepatocellular carcinoma (HCC), which are associated with high mortality rates. HBV is a non-cytopathic virus, with the host's immune response responsible for the associated liver damage. Indeed, HBV appears to be a master of manipulating and modulating the immune response to achieve persistent and chronic infection. The HBV precore protein or hepatitis B e antigen (HBeAg) is a key viral protein involved in these processes, for instance though the down-regulation of the innate immune response. The development of new therapies that target viral proteins, such as HBeAg, which regulates of the immune system, may offer a new wave of potential therapeutics to circumvent progression to CHB and liver disease.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Proteínas Virais
/
DNA
/
Regulação para Baixo
/
Vírus da Hepatite B
/
Saúde Global
/
Mortalidade
/
Carcinoma Hepatocelular
/
Hepatite B Crônica
/
Hepatite
/
Hepatite B
Tipo de estudo:
Estudo prognóstico
Idioma:
Inglês
Revista:
Yonsei Medical Journal
Ano de publicação:
2012
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS